0 CHECKOUT

Cedar Pollen Allergy - Pipeline Review, H1 2015

  • ID: 3280646
  • May 2015
  • 51 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Allergy Therapeutics plc
  • Anergis SA
  • Biomay AG
  • Japan Tobacco Inc.
  • REGiMMUNE Corporation
  • Stallergenes S.A.
  • MORE

Cedar Pollen Allergy - Pipeline Review, H1 2015

Summary

This, ‘Cedar Pollen Allergy - Pipeline Review, H1 2015’, provides an overview of the Cedar Pollen Allergy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergy Therapeutics plc
  • Anergis SA
  • Biomay AG
  • Japan Tobacco Inc.
  • REGiMMUNE Corporation
  • Stallergenes S.A.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Cedar Pollen Allergy Overview
Therapeutics Development
Pipeline Products for Cedar Pollen Allergy - Overview
Pipeline Products for Cedar Pollen Allergy - Comparative Analysis
Cedar Pollen Allergy - Therapeutics under Development by Companies
Cedar Pollen Allergy - Therapeutics under Investigation by Universities/Institutes
Cedar Pollen Allergy - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Cedar Pollen Allergy - Products under Development by Companies
Cedar Pollen Allergy - Products under Investigation by Universities/Institutes
Cedar Pollen Allergy - Companies Involved in Therapeutics Development
Allergy Therapeutics plc
Anergis SA
Biomay AG
Circassia Pharmaceuticals plc
Immunomic Therapeutics, Inc.
Japan Tobacco Inc.
REGiMMUNE Corporation
Stallergenes S.A.
Cedar Pollen Allergy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AllerJ - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP-4070 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Cedar Pollen Allergy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Japanese cedar hypoallergenic vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JCC-LAMP-Vax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MC-LAMP-Vax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pollinex Quattro Japanese Cedar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RGI-1001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STG-120 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TO-206 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Cedar Pollen Allergy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Cedar Pollen Allergy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cedar Pollen Allergy - Recent Pipeline Updates
Cedar Pollen Allergy - Dormant Projects
Cedar Pollen Allergy - Dormant Projects
Cedar Pollen Allergy - Product Development Milestones
Featured News & Press Releases
Mar 09, 2015: Immunomic Therapeutics to Present at BIO-Europe Annual Conference
Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting
Apr 24, 2013: Immunomic Therapeutics Announces Interim Data Analysis Of Phase I Study To Treat Japanese Red Cedar Allergy
Nov 08, 2012: Immunomic Therapeutics Doses First Patient In Phase I Clinical Trial Of JRC-LAMP-Vax Vaccine To Treat Japanese Red Cedar Allergy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Cedar Pollen Allergy, H1 2015
Number of Products under Development for Cedar Pollen Allergy - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Cedar Pollen Allergy - Pipeline by Allergy Therapeutics plc, H1 2015
Cedar Pollen Allergy - Pipeline by Anergis SA, H1 2015
Cedar Pollen Allergy - Pipeline by Biomay AG, H1 2015
Cedar Pollen Allergy - Pipeline by Circassia Pharmaceuticals plc, H1 2015
Cedar Pollen Allergy - Pipeline by Immunomic Therapeutics, Inc., H1 2015
Cedar Pollen Allergy - Pipeline by Japan Tobacco Inc., H1 2015
Cedar Pollen Allergy - Pipeline by REGiMMUNE Corporation, H1 2015
Cedar Pollen Allergy - Pipeline by Stallergenes S.A., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Cedar Pollen Allergy Therapeutics - Recent Pipeline Updates, H1 2015
Cedar Pollen Allergy - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Cedar Pollen Allergy, H1 2015
Number of Products under Development for Cedar Pollen Allergy - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

- Allergy Therapeutics plc
- Anergis SA
- Biomay AG
- Circassia Pharmaceuticals plc
- Immunomic Therapeutics, Inc.
- Japan Tobacco Inc.
- REGiMMUNE Corporation
- Stallergenes S.A.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Merck & Co., Inc.
  • Celgene Corporation
  • GlaxoSmithKline PLC
  • Genentech, Inc.
  • Johnson & Johnson Services, Inc.
  • ViiV Healthcare